Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PWS Clear all
Completed No phase listed Observational

Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity

NCT00375089
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
Group 1, Group 2
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 60 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Orange, California • Gainesville, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 24, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

NCT05879614
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
NNZ-2591
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
4 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
San Diego, California • Atlanta, Georgia • Chevy Chase, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome

NCT00065923
View directory record Official record
Conditions
Prader-Willi Syndrome, Self-Injurious Behavior
Interventions
Topiramate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 66 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Not applicable Interventional

Home-based SSP on Individuals With PWS

NCT03871751
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Safe and Sound Protocol
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

NCT05504395
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
CSTI-500
Drug
Lead sponsor
ConSynance Therapeutics
Industry
Eligibility
13 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

NCT01401244
View directory record Official record
Conditions
Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational

Hypoglycemia in Prader-Willi Syndrome

NCT01897363
View directory record Official record
Conditions
Prader Willi Syndrome, Hypoglycemia
Interventions
Infants with Prader-Willi Syndrome
Other
Lead sponsor
University of Florida
Other
Eligibility
2 Months to 12 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

NCT02844933
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Tucson, Arizona • San Diego, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Personalized Interactive Laser Therapy of Port Wine Stain

NCT00782483
View directory record Official record
Conditions
Port Wine Stain
Interventions
ThermoVision A20M Infrared Camera, ScleroPLUS, 3D Digital Camera
Device
Lead sponsor
University of Arkansas
Other
Eligibility
3 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

NCT05322096
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RGH-706, Placebo
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
17 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Brooklyn, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

NCT01818921
View directory record Official record
Conditions
Obesity, Over-weight, Prader-Willi Syndrome
Interventions
ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Cerebellar TMS and Satiety in Prader-Willi Syndrome

NCT05938543
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT06828861
View directory record Official record
Conditions
Hyperphagia, Prader-Willi Syndrome
Interventions
Placebo, ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Encinitas, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT06772597
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity, Hyperphagia
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PWS Outcomes Assessment Study

NCT04102839
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Interview
Other
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Plymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome

NCT02368379
View directory record Official record
Conditions
Prader Willi Syndrome, Adrenal Insufficiency
Interventions
Low dose (1 mcg) ACTH stimulation test, Overnight metyrapone test
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 24, 2026, 4:14 AM EDT
Withdrawn Phase 4 Interventional

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Guanfacine extended release (GXR)
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain-Derived Neurotrophic Factor in Obesity and Brain Function

NCT01517048
View directory record Official record
Conditions
Obesity, Genetic Disorder, Mental Retardation, Developmental Delay
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 99 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

NCT00004351
View directory record Official record
Conditions
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

NCT02670694
View directory record Official record
Conditions
Rett Syndrome, Prader-Willi Syndrome, Angelman Syndrome, Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
804 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

NCT03274856
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
GLWL-01, Placebo
Drug
Lead sponsor
GLWL Research Inc.
Other
Eligibility
16 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
San Diego, California • Gainesville, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome

NCT05541003
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
NBT-NM108
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jul 24, 2026, 4:14 AM EDT